Sorrento Therapeutics, Inc. (SRNE)

NASDAQ: SRNE · IEX Real-Time Price · USD
1.55
+0.04 (2.65%)
At close: Sep 27, 2022 4:00 PM
1.57
+0.02 (1.29%)
After-hours: Sep 27, 2022 4:02 PM EDT
2.65%
Market Cap 697.43M
Revenue (ttm) 54.98M
Net Income (ttm) -523.79M
Shares Out 449.95M
EPS (ttm) -1.53
PE Ratio n/a
Forward PE 1.10
Dividend n/a
Ex-Dividend Date n/a
Volume 5,632,169
Open 1.61
Previous Close 1.51
Day's Range 1.50 - 1.62
52-Week Range 1.15 - 8.12
Beta 2.26
Analysts Buy
Price Target 15.81 (+920.0%)
Earnings Date Aug 5, 2022

About SRNE

Sorrento Therapeutics, Inc., a clinical stage and commercial biopharmaceutical company, develops therapies for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugate, as well as bispecific antibody approa... [Read more...]

Industry Biotechnology
Founded 2006
CEO Henry Ji
Employees 799
Stock Exchange NASDAQ
Ticker Symbol SRNE
Full Company Profile

Financial Performance

In 2021, SRNE's revenue was $52.90 million, an increase of 32.31% compared to the previous year's $39.99 million. Losses were -$428.33 million, 43.5% more than in 2020.

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for SRNE stock is "Buy." The 12-month stock price forecast is 15.81, which is an increase of 920.00% from the latest price.

Price Target
$15.81
(920.00% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Sorrento Therapeutics Completes Enrollment of Phase 2 Clinical Trial of Resiniferatoxin (RTX) for Treatment of Knee P...

SAN DIEGO, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") announced today that the company has completed enrollment of its latest Phase 2 clinical study of RTX...

1 day ago - GlobeNewsWire

Sorrento Announces the Publication in the Nature Journal Scientific Reports the Details of the Discovery of SARS-CoV-...

SAN DIEGO, Sept. 15, 2022 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced publication of peer-reviewed data detailing the discovery and preclinical profiling o...

1 week ago - GlobeNewsWire

Sorrento Reports Positive Trial Results Utilizing Sofusa Lymphatic Delivery of Etanercept, Achieving Significant Impr...

SAN DIEGO, Sept. 15, 2022 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced completion of its first Phase 1b proof of concept study using the Sofusa Lymphatic Dr...

1 week ago - GlobeNewsWire

Sorrento Therapeutics to Participate in Morgan Stanley 20th Annual Global Healthcare Conference September 12-14

SAN DIEGO, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today announced that Henry Ji, Ph.D., Chairman, President and Chief Executive Officer, and members of...

2 weeks ago - GlobeNewsWire

Sorrento (SRNE) Gets FDA Fast Track Tag for Back Pain Product

Sorrento Therapeutics' (SRNE) subsidiary Scilex receives Fast Track designation for its lower back pain (LBP) candidate, SP-103. Stock Up.

3 weeks ago - Zacks Investment Research

Why Sorrento Therapeutics Stock Is Marching Higher Today

An FDA fast track designation for a high-value product candidate is powering the biotech's shares higher today.

3 weeks ago - The Motley Fool

Sorrento Therapeutics (SRNE) Pops on FDA Fast Track Designation

Source: Bukhta Yurii / Shutterstock.com Sorrento Therapeutics (NASDAQ: SRNE ) stock is getting a boost on Wednesday after the FDA granted it fast-track designation for SP-103. SP-103 is Sorrento Therape...

3 weeks ago - InvestorPlace

Scilex Holding Company, a Sorrento Company, Announces That the FDA Has Granted Fast Track Designation for SP-103 (Lid...

PALO ALTO, Calif., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex”), a commercial biopharmaceutical company focused on developing and commercializing non-opioid therapies for patients...

3 weeks ago - GlobeNewsWire

Sorrento (SRNE) Up on Positive Result From Lung Cancer Study

Sorrento Therapeutics' (SRNE) stock rises after it announced positive results from its late-stage lung cancer study evaluating abivertinib.

1 month ago - Zacks Investment Research

2 Penny Stocks That Could Make You Filthy Rich

These two penny stocks could generate life-changing gains for early shareholders.

Other symbols: SNDL
1 month ago - The Motley Fool

Why Sorrento Therapeutics Stock Is Popping Today

A positive clinical readout in lung cancer is fueling the biotech's rally today.

1 month ago - The Motley Fool

Sorrento Announces Significant Positive Pivotal Trial Results as Assessed by an Independent Review Committee (IRC) Wi...

SAN DIEGO, Aug. 23, 2022 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced positive results from a pivotal study of Abivertinib on 209 response evaluable, heavil...

1 month ago - GlobeNewsWire

Sorrento Therapeutics Announces China National Medical Products Administration (NMPA) IND Clearance of STI-1558, An O...

SAN DIEGO, Aug. 19, 2022 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced the NMPA clearance of a Phase I study of its oral main viral protease (Mpro) inhibitor...

1 month ago - GlobeNewsWire

Scilex Holding Company, a Sorrento Company, Announces Exclusive Product Distribution Agreement with CH Trading Group ...

PALO ALTO, Calif., Aug. 17, 2022 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex”), a commercial biopharmaceutical company focused on developing and commercializing non-opioid therapies for patients...

1 month ago - GlobeNewsWire

Scilex Holding Company, a Sorrento Company, Announces Expanding Coverage to 30 Million Lives And Will Continue To Wor...

PALO ALTO, Calif., Aug. 16, 2022 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex”), a subsidiary of Sorrento Therapeutics, Inc. (NASDAQ: SRNE, “Sorrento”), announced that, effective September 1, 202...

1 month ago - GlobeNewsWire

Sorrento Completes Successfully the SAD Study and Initiates the MAD Phase 1 Study with STI-1558, An Oral M(pro) Inhib...

SAN DIEGO, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced the completion of the SAD portion of the Phase 1 study of its oral main viral protease...

1 month ago - GlobeNewsWire

10 Stocks to Sell Before They Die

This article is excerpted from Tom Yeung's Profit & Protection newsletter dated July 28, 2022. To make sure you don't miss any of Tom's picks, subscribe to his mailing list here.

1 month ago - InvestorPlace

Sorrento (SRNE) Rises on FDA IND Clearance for COVID Drug

Sorento Therapeutics (SRNE) receives IND application clearance from the FDA for a phase I study evaluating STI-1558 for COVID-19.

2 months ago - Zacks Investment Research

FDA Clears Sorrento's STI-1558 Phase 1 Study To Treat COVID-19 Infection

The FDA has signed off Sorrento Therapeutics Inc's (NASDAQ: SRNE) Phase 1 study of its oral main viral protease (Mpro) inhibitor, STI-1558, in patients with impaired renal and hepatic function. The Phas...

2 months ago - Benzinga

Sorrento Therapeutics Announces the FDA IND Clearance of STI-1558, An Oral M(pro) and Cathepsin L Inhibitor to Treat ...

SAN DIEGO, July 19, 2022 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced the FDA clearance of a Phase 1 study of its oral main viral protease (Mpro) inhibitor,...

2 months ago - GlobeNewsWire

Why Ocugen, Sorrento Therapeutics, and VBI Vaccines Are on the Move Today

Healthcare has become a bona fide stock picker's market this year.

Other symbols: OCGNVBIV
2 months ago - The Motley Fool

Scilex Holding Company, a Sorrento Company, Has Entered A Term Sheet to Acquire Ancora Medical Inc.

PALO ALTO, Calif., July 07, 2022 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex”), a nearly 100% (or over 99.9%) majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”),...

2 months ago - GlobeNewsWire

Scilex Holding Company, a Sorrento Company, announces that the Honorable Tommy G. Thompson has joined the Scilex Boar...

PALO ALTO, Calif., July 05, 2022 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex”), a nearly 100% (or over 99.9%) majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”),...

2 months ago - GlobeNewsWire

Why Sorrento Therapeutics Stock Is Jumping Today

The biotech's bargain-basement valuation appears to be attracting investors' interest.

2 months ago - The Motley Fool

Sorrento Therapeutics, Inc. announces the appointment of the Honorable Tommy G. Thompson, as Covid-19 Special Consult...

SAN DIEGO, June 24, 2022 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), a commercial and clinical-stage biopharmaceutical company dedicated to developing and commercializing...

3 months ago - GlobeNewsWire